417 related articles for article (PubMed ID: 19944595)
21. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.
Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
Eur J Nucl Med; 2000 Nov; 27(11):1598-609. PubMed ID: 11105815
[TBL] [Abstract][Full Text] [Related]
22. [Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)].
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Kaku Igaku; 1998 Jul; 35(6):395-404. PubMed ID: 9753918
[TBL] [Abstract][Full Text] [Related]
23. [Impact of FDG-PET on radiation therapy: economic results of a STIC study].
Remonnay R; Morelle M; Giammarile F; Pommier P; Carrère MO
Cancer Radiother; 2009 Jul; 13(4):313-7. PubMed ID: 19493691
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
[TBL] [Abstract][Full Text] [Related]
25. [Cost-effectiveness of PET in the management algorithms of lung tumors: comparison of health economic data].
Dietlein M; Moka D; Weber K; Theissen P; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):122-8. PubMed ID: 11556202
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
Nguyen VH; Peloquin S; Lacasse Y
Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
[TBL] [Abstract][Full Text] [Related]
27. Suspected carotid artery stenosis: cost-effectiveness of CT angiography in work-up of patients with recent TIA or minor ischemic stroke.
Tholen AT; de Monyé C; Genders TS; Buskens E; Dippel DW; van der Lugt A; Hunink MG
Radiology; 2010 Aug; 256(2):585-97. PubMed ID: 20656842
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
[TBL] [Abstract][Full Text] [Related]
29. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.
Everitt S; Herschtal A; Callahan J; Plumridge N; Ball D; Kron T; Schneider-Kolsky M; Binns D; Hicks RJ; MacManus M
Cancer; 2010 Nov; 116(21):5030-7. PubMed ID: 20623786
[TBL] [Abstract][Full Text] [Related]
30. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
Decoster L; Schallier D; Everaert H; Nieboer K; Meysman M; Neyns B; De Mey J; De Grève J
Lung Cancer; 2008 Oct; 62(1):55-61. PubMed ID: 18394750
[TBL] [Abstract][Full Text] [Related]
31. (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT.
Hanna GG; McAleese J; Carson KJ; Stewart DP; Cosgrove VP; Eakin RL; Zatari A; Lynch T; Jarritt PH; Young VA; O'Sullivan JM; Hounsell AR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):24-30. PubMed ID: 19665324
[TBL] [Abstract][Full Text] [Related]
32. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
35. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
[TBL] [Abstract][Full Text] [Related]
36. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
Gómez-Caro A; Garcia S; Reguart N; Arguis P; Sanchez M; Gimferrer JM; Marrades R; Lomeña F
Eur J Cardiothorac Surg; 2010 May; 37(5):1168-74. PubMed ID: 20116273
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
[TBL] [Abstract][Full Text] [Related]
38. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
39. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2007 Oct; 84(4):1092-7. PubMed ID: 17888953
[TBL] [Abstract][Full Text] [Related]
40. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
